Evidence map›Paper›PMID 30931493›Full record

ReviewCurrent treatment options in oncology2019

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Noam Pondé, Philippe Aftimos, Martine Piccart

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05174637 (A PhaseⅠStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of FDA018-ADC in Patients With Advanced Solid Tumors), which is not on this map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05174637 phase1active not recruitingnot on this mapstarted 2021, after this paper: background citation

A PhaseⅠStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of FDA018-ADC in Patients With Advanced Solid Tumors

TypeinterventionalSponsorShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.Ran2021 to 2029Enrolled78ConditionsAdvanced/ Metastatic Solid TumorsArmsFDA018-ADC
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Clathrin light chain-conjugated drug delivery for cancer.Bioengineering & translational medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Noam PondéDepartment of Research, Institut Jules Bordet; Université Libre de Bruxelles, Boulevard de Waterloo, 121 1000, Brussels, Belgium.
Philippe AftimosDepartment of Research, Institut Jules Bordet; Université Libre de Bruxelles, Boulevard de Waterloo, 121 1000, Brussels, Belgium.
Martine PiccartDepartment of Research, Institut Jules Bordet; Université Libre de Bruxelles, Boulevard de Waterloo, 121 1000, Brussels, Belgium. Martine.piccart@bordet.be.
Université Libre de Bruxelles · BEInstitut Jules Bordet · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementAntibody-drug conjugates are an elegant approach to cancer treatment that couples the specificity of monoclonal antibodies to the cytotoxicity of classic chemotherapy agents, permitting, at least in theory, increased activity and reduced toxicity. In breast cancer, the early success of trastuzumab-emtansine (T-DM1) in the HER2-positive metastatic setting led to great hopes, later dashed by results in the early setting (KRISTINE trial) and in combination with pertuzumab (MARIANNE trial). Parallel to this, development of ADCs in breast cancer has suffered other setbacks, including the recent failure of other agents (MM-302) as well as the suspension of a few programs (XMT-1522, ADCT-502) with the overall effect of dampening the impetus of this concept and halting/delaying the progress of drugs associated with it, particularly when immunotherapy is at the center of so many efforts. Numerous antibody-drug conjugates remain, however, in development, and could prove successful. Critically, ADCs could permit the introduction of novel concepts such as the expansion of potent anti-HER2 therapy to HER2-low breast cancer, treatment beyond resistance to T-DM1, and synergy in combination with immune checkpoint blockade. In the early setting, the ATEMPT trial may show that T-DM1 reduces toxicity while maintaining good outcomes for lower risk HER2+ patients. ADCs based on bispecific antibodies are also in development. Finally, breakthroughs are occurring in the orphan triple-negative breast cancer subtype with agents targeting surface proteins. The recent results of Sacituzumab govitecan suggest substantial activity in heavily pre-treated patients and underscore the enduring relevance of antibody drug conjugates as a path towards better outcomes.

Indexed as

Antibody-Dependent Cell CytotoxicityAntineoplastic Agents, ImmunologicalBiomarkers, TumorBreast NeoplasmsBystander EffectClinical Trials as TopicCombined Modality TherapyDiagnostic ImagingDrug DevelopmentFemaleHumansImmunoconjugatesMolecular Targeted TherapyNeoplasm StagingAntineoplastic Agents, ImmunologicalBiomarkers, TumorImmunoconjugatesAntibody-drug conjugatesBreast cancerDS–8201aSacituzumab govitecanSYD0985T-DM1

Identifiers

PMID30931493
OpenAlexW2929029059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.